Cytori Therapeutics said today it plans to acquire the liposomal nanoparticle technology platform of Azaya Therapeutics for up to $170 million, in a deal designed to expand and complement the buyer’s ...
SAN ANTONIO--(BUSINESS WIRE)--Azaya Therapeutics Inc., a clinical-stage oncology company developing more effective cancer treatments through its nanotechnology platform, announced an exclusive license ...
Parexo Labs, a division of Azaya, launches as a new CDMO with an emphasis on nanotechnology and liposomal manufacturing. Azaya Therapeutics, a biopharmaceutical company focused on focused on ...
Cytori thinks the acquited platform will enable delivery of regenerative medicines () Cytori Therapeutics is set to gain cancer drugs and a liposomal nanoparticle technology platform through the ...
Cytori Therapeutics Inc. stock surged 7.9% to $1.78 per share in morning trade Thursday after the company said it had agreed to purchase assets from privately-held Azaya Therapeutics. Under the terms ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Azaya Therapeutics is conducting a study of a generic ...
> We all know that one of the most valuable resources in the clinical research industry is experienced staff. Yet it is commonly accepted that a clinical monitor will only stay with a company for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results